Curi Bio Acquires South Korea-based Quvit Bio

BioIVT Acquires ZenBio

August 21, 2024

Healthcare Services

BioIVT has acquired ZenBio, a Durham-based provider of advanced cell products and biospecimen services, to expand its skin-based expertise, primary cell and exosome isolation capabilities, and blood product offerings for pharmaceutical and cosmetics research. The deal strengthens BioIVT's service portfolio and complements recent integrations to accelerate support for drug discovery and cosmeceutical development; financial terms were not disclosed.

Curi (Curi Capital) Acquires RMB Capital to Form Curi RMB Capital

January 2, 2024

Wealth Management

Curi completed its previously announced acquisition of RMB Capital and merged Curi Capital with RMB to form Curi RMB Capital, a registered investment advisory firm with more than $11.3 billion in assets under advisement. The combined firm is headquartered in Chicago, retains leadership from both organizations, and has approximately 180 employees while positioning itself for expanded geographic reach and long-term growth.

GC Corp Signs Definitive Agreement to Acquire BioCentriq, Inc.

April 19, 2022

Healthcare Services

GC corp., the holding (system) company for the GC group in South Korea, signed a definitive agreement to acquire 100% of the shares of BioCentriq, Inc. BioCentriq is a US-based CDMO focused on scalable cell and gene technology development and cGMP-grade clinical manufacturing.

Curia (formerly AMRI) to Acquire Integrity Bio, Inc.

July 13, 2021

Healthcare Services

Curia (formerly AMRI) has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization headquartered in Camarillo, California. The acquisition is intended to expand Curia’s biologics drug product formulation development and enhance its fill-finish network, including adding West Coast coverage.

Curi Bio Acquires Dana Solutions

July 23, 2020

Biotechnology

Curi Bio, a Seattle-based developer of human iPSC platforms for drug discovery, has acquired Dana Solutions to integrate Dana's AI/ML platforms (PhenoLearn, Pulse, PhenoTox) into Curi's human cell- and tissue-based discovery and safety-testing offerings. The deal (terms undisclosed) will allow Curi to offer combined predictive human iPSC-derived models and AI-enabled phenotypic data insights and will continue a prior FDA-funded collaboration to validate PhenoTox.

Curative Inc. Acquires KorvaLabs, Inc.

May 19, 2020

Healthcare Services

Curative Inc. has acquired KorvaLabs, a CLIA-certified and DEA-licensed analytical laboratory based in San Dimas, California, formalizing a partnership that supported Curative's manufacture and processing of its oral fluid COVID-19 test. The acquisition strengthens Curative's testing capacity — to date the organizations processed 245,371 tests together and were processing roughly 14,000 tests per day — and secures in-house manufacturing and processing capabilities.